RNAC
More staying power, less fade-away
Cartesian Therapeutics reported additional retreatment data for its investigational CAR-T therapy Descartes-08, and the headline is basically: the response held up. In generalized myasthenia gravis, durability matters a lot — if a treatment works but the effect disappears faster than your phone battery on 3%? Not great.
Why investors should care
Biotech stocks often trade on two things: does the drug work, and does it keep working? This update leans into the second question. Sustained improvements can help build the case that Descartes-08 has real-world staying power in MG, which is a big deal for a company trying to turn early clinical optimism into actual value.
The fine print still matters
This is still investigational data, so no one’s ringing the revenue bell yet. But durable responses can matter a lot for how the market prices the odds of a larger trial win, a future filing, or even partnering interest down the road.
Big picture: biotech investors don’t just want a spark — they want a campfire. Cartesian is trying to show Descartes-08 can be that.